Status Epilepticus: What's New?

Emergency Medicine Clinics of North America

Volumn 34, Issue 4, 2016, Pages 759-776

  Khoujah, Danya ^a   Abraham, Michael K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Epilepsy; Seizures; Status epilepticus

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CREATINE KINASE; FOSPHENYTOIN SODIUM; INTRAVENOUS ANESTHETIC AGENT; KETAMINE; LACOSAMIDE; LEVETIRACETAM; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PROPOFOL; VALPROIC ACID; NEUROLEPTIC AGENT;

BRAIN METABOLISM; CELL DAMAGE; CLINICAL PROTOCOL; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST; DRUG RESPONSE; ENDOTRACHEAL INTUBATION; EPILEPSY; EPILEPTIC STATE; GENERALIZED CONVULSIVE STATUS EPILEPTICUS; HUMAN; MEDICAL HISTORY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATION CONTROL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; HOSPITAL EMERGENCY SERVICE; STATUS EPILEPTICUS;

ANTIPSYCHOTIC AGENTS; EMERGENCY SERVICE, HOSPITAL; HUMANS; STATUS EPILEPTICUS;

EID: 84992437528     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2016.06.012     Document Type: Review

References (65)

1. 1 Angus-Leppan, H., First seizures in adults. BMJ, 348, 2014, g2470.
2. 2 Fisher, R.S., Acevedo, C., Arzimanoglou, A., et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:4 (2014), 475–482.
3. 3 Logroscino, G., Hesdorffer, D.C., Cascino, G., et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia 46:Suppl 11 (2005), 46–48.
4. 4 Hocker, S.E., Britton, J.W., Mandrekar, J.N., et al. Predictors of outcome in refractory status epilepticus. JAMA Neurol 70:1 (2013), 72–77.
5. 5 Koubeissi, M., Alshekhlee, A., In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurol 69:9 (2007), 886–893.
6. Chen, J.W., Wasterlain, C.G., Status epilepticus: pathophysiology and management in adults. Lancet Neurol 5:3 (2006), 246–256.
7. 7 Huff, J.S., Fountain, N.B., Pathophysiology and definitions of seizures and status epilepticus. Emerg Med Clin North Am 29:1 (2011), 1–13.
8. 8 Chen, J.W.Y., Naylor, D.E., Wasterlain, C.G., Advances in the pathophysiology of status epilepticus. Acta Neurol Scand 115 (2007), 7–15.
9. 9 Deeb, T.Z., Maguire, J., Moss, S.J., Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia 53:s9 (2012), 79–88.
10. 10 Löscher, W., Potschka, H., Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:8 (2005), 591–602.
11. 11 Mazarati, A.M., Baldwin, R.A., Sankar, R., et al. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res 814:1 (1998), 179–185.
12. 12 Kapur, J., Macdonald, R.L., Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 17:19 (1997), 7532–7540.
13. 13 Naylor, D.E., Liu, H., Niquet, J., et al. Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis 54 (2013), 225–238.
14. 14 Mazarati, A.M., Wasterlain, C.G., N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 265:3 (1999), 187–190.
15. 15 Brophy, G.M., Bell, R., Claassen, J., et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17:1 (2012), 3–23.
16. 16 Shearer, P., Riviello, J., Generalized convulsive status epilepticus in adults and children: treatment guidelines and protocols. Emerg Med Clin North Am 29:1 (2011), 51–64.
17. 17 Hocker, S.E., Status epilepticus. Continuum (Minneap Minn) 21:5 Neurocritical Care (2015), 1362–1383.
18. 18 Glauser, T., Shinnar, S., Gloss, D., et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society. Epilepsy Curr 16:1 (2016), 48–61.
19. 19 Aranda, A., Foucart, G., Ducassé, J.L., et al. Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. Epilepsia 51:10 (2010), 2159–2167.
20. 20 Treiman, D.M., Meyers, P.D., Walton, N.Y., et al. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 339:12 (1998), 792–798.
21. 21 Alldredge, B.K., Gelb, A.M., Isaacs, S.M., et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 345:9 (2001), 631–637.
22. 22 Reves, J.G., Fragen, R.J., Vinik, H.R., et al. Midazolam: pharmacology and uses. Anesthesiology 62:3 (1985), 310–324.
23. 23 Towne, A.R., DeLorenzo, R.J., Use of intramuscular midazolam for status epilepticus. J Emerg Med 17:2 (1999), 323–328.
24. 24 Gamble, J., Dundee, J., Assaf, R., Plasma diazepam levels after single dose oral and intramuscular administration. Anaesthesia 30:2 (1975), 164–169.
25. 25 Silbergleit, R., Durkalski, V., Lowenstein, D., et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 366:7 (2012), 591–600.
26. 26 Gottwald, M.D., Akers, L.C., Liu, P., et al. Prehospital stability of diazepam and lorazepam. Am J Emerg Med 17:4 (1999), 333–337.
27. Jahns, B.E., Bakst, C.M., Extension of expiration time for lorazepam injection at room temperature. Am J Hosp Pharm, 50(6), 1993, 1134.
28. 28 Wolfe, T.R., Macfarlane, T.C., Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med 24:3 (2006), 343–346.
29. 29 Knoester, P., Jonker, D., Van der Hoeven, R., et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. a study in healthy volunteers. Br J Clin Pharmacol 53:5 (2002), 501–507.
30. 30 Bleck, T., Cock, H., Chamberlain, J., et al. The established status epilepticus trial 2013. Epilepsia 54:s6 (2013), 89–92.
31. 31 Mayer, S.A., Claassen, J., Lokin, J., et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 59:2 (2002), 205–210.
32. 32 Marchetti, A., Magar, R., Fischer, J., et al. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx®) versus intravenous phenytoin (Dilantin®) in hospital emergency departments. Clin Ther 18:5 (1996), 953–966.
33. 33 Earnest, M.P., Marx, J.A., Drury, L.R., Complications of intravenous phenytoin for acute treatment of seizures: recommendations for usage. JAMA 249:6 (1983), 762–765.
34. 34 Knake, S., Hamer, H.M., Rosenow, F., Status epilepticus: a critical review. Epilepsy Behav 15:1 (2009), 10–14.
35. 35 Agarwal, P., Kumar, N., Chandra, R., et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 16:6 (2007), 527–532.
36. 36 Huff, J.S., Melnick, E.R., Tomaszewski, C.A., et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med 63:4 (2014), 437–447.e15.
37. 37 Trinka, E., Höfler, J., Zerbs, A., et al. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs 28:7 (2014), 623–639.
38. 38 Yasiry, Z., Shorvon, S.D., The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 23:3 (2014), 167–174.
39. 39 Gábor, G., Judit, T., Zsolt, I., Comparison of propofol and etomidate regarding impact on seizure threshold during electroconvulsive therapy in patients with schizophrenia. Neuropsychopharmacol Hung 9:3 (2007), 125–130.
40. 40 Betjemann, J.P., Lowenstein, D.H., Status epilepticus in adults. Lancet Neurol 14:6 (2015), 615–624.
41. 41 Alvarez, V., Januel, J., Burnand, B., et al. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia 52:7 (2011), 1292–1296.
42. 42 Tripathi, M., Vibha, D., Choudhary, N., et al. Management of refractory status epilepticus at a tertiary care centre in a developing country. Seizure 19:2 (2010), 109–111.
43. 43 Höfler, J., Trinka, E., Lacosamide as a new treatment option in status epilepticus. Epilepsia 54:3 (2013), 393–404.
44. 44 Kellinghaus, C., Berning, S., Stögbauer, F., Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand 129:5 (2014), 294–299.
45. 45 Miró, J., Toledo, M., Santamarina, E., et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure 22:1 (2013), 77–79.
46. 46 Garcés, M., Villanueva, V., Mauri, J.A., et al. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. Epilepsy Behav 36 (2014), 144–152.
47. 47 Legros, B., Depondt, C., Levy-Nogueira, M., et al. Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses. Neurocrit Care 20:3 (2014), 484–488.
48. Zeiler, F., Teitelbaum, J., Gillman, L., et al. NMDA antagonists for refractory seizures. Neurocrit Care 20:3 (2014), 502–513.
49. 49 Zeiler, F., Early use of the NMDA receptor antagonist ketamine in refractory and superrefractory status epilepticus. Crit Care Res Pract, 2015, 2015, 831260.
50. 50 Zeiler, F.A., Teitelbaum, J., West, M., et al. The ketamine effect on intracranial pressure in nontraumatic neurological illness. J Crit Care 29:6 (2014), 1096–1106.
51. 51 Kowalski, R.G., Ziai, W.C., Rees, R.N., et al. Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasopressor use and prolonged mechanical ventilation. Crit Care Med 40:9 (2012), 2677–2684.
52. 52 Sutter, R., Marsch, S., Fuhr, P., et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 82:8 (2014), 656–664.
53. 53 Kumar, A., Bleck, T.P., Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 20:4 (1992), 483–488.
54. 54 Rossetti, A.O., Reichhart, M.D., Schaller, M., et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 45:7 (2004), 757–763.
55. 55 Prabhakar, H., Bindra, A., Singh, G.P., et al. Propofol versus thiopental sodium for the treatment of refractory status epilepticus (Review). Evid Based Child Health 8:4 (2013), 1488–1508.
56. 56 Iyer, V.N., Hoel, R., Rabinstein, A.A., Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med 37:12 (2009), 3024–3030.
57. 57 Mäkelä, J., Iivanainen, M., Pieninkeroinen, I., et al. Seizures associated with propofol anesthesia. Epilepsia 34:5 (1993), 832–835.
58. 58 Pugin, D., Foreman, B., De Marchis, G.M., et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. Crit Care, 18(3), 2014, R103.
59. 59 Claassen, J., Hirsch, L.J., Emerson, R.G., et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 43:2 (2002), 146–153.
60. 60 Parviainen, I., Uusaro, A., Kalviainen, R., et al. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology 59:8 (2002), 1249–1251.
61. 61 Bennett, A.E., Hoesch, R.E., DeWitt, L.D., et al. Therapeutic hypothermia for status epilepticus: a report, historical perspective, and review. Clin Neurol Neurosurg 126 (2014), 103–109.
62. 62 Kossoff, E.H., Nabbout, R., Use of dietary therapy for status epilepticus. J Child Neurol 28:8 (2013), 1049–1051.
63. 63 Ferguson, M., Bianchi, M.T., Sutter, R., et al. Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus. Neurocrit Care 18:2 (2013), 216–227.
64. 64 Meierkord, H., Boon, P., Engelsen, B., et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 17:3 (2010), 348–355.
65. 65 Nandhagopal, R., Generalised convulsive status epilepticus: an overview. Postgrad Med J 82:973 (2006), 723–732 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660499/.